Last reviewed · How we verify

Budesonide, Formoterol Fumarate Dihydrate

Teva Pharma GmbH · FDA-approved active Small molecule Quality 5/100

Budesonide, Formoterol Fumarate Dihydrate is a Small molecule drug developed by Teva Pharma GmbH. It is currently FDA-approved. Also known as: DuoResp® Spiromax®.

At a glance

Generic nameBudesonide, Formoterol Fumarate Dihydrate
Also known asDuoResp® Spiromax®
SponsorTeva Pharma GmbH
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Budesonide, Formoterol Fumarate Dihydrate

What is Budesonide, Formoterol Fumarate Dihydrate?

Budesonide, Formoterol Fumarate Dihydrate is a Small molecule drug developed by Teva Pharma GmbH.

Who makes Budesonide, Formoterol Fumarate Dihydrate?

Budesonide, Formoterol Fumarate Dihydrate is developed and marketed by Teva Pharma GmbH (see full Teva Pharma GmbH pipeline at /company/teva-pharma-gmbh).

Is Budesonide, Formoterol Fumarate Dihydrate also known as anything else?

Budesonide, Formoterol Fumarate Dihydrate is also known as DuoResp® Spiromax®.

What development phase is Budesonide, Formoterol Fumarate Dihydrate in?

Budesonide, Formoterol Fumarate Dihydrate is FDA-approved (marketed).

Related